Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States.
2025 · PubMed · 1 citations
https://doi.org/10.18553/jmcp.2025.31.3.262